A 2-Year Analysis of 30-Day Hospital Readmissions and Cost Benefits of Septicemia OPAT in a POIC

SAN DIEGO, CA (October 10, 2015) – Septicemia constitutes a major cause for 30-day hospital readmissions and is the most expensive condition treated in U.S. hospitals according to the Agency for Healthcare Research and Quality, Healthcare Cost, and Utilization Project. A two-year, multi-center, retrospective study was conducted of 525 septicemia patients receiving outpatient antimicrobial therapy (OPAT) through 12 Infectious Disease (ID) Physician Office Infusion Centers (POIC). Evaluation included unplanned 30-day hospital readmissions, length of stay, risk factors contributing to the readmissions, and costs.

Study results indicated a 13.5 percent 30-day hospital readmission rate. This differed significantly from national 30-day readmission rates for septicemia of 19.7 percent. Upon readmission, average hospital stay for patients receiving OPAT through a POIC were 8.1 days versus 11.1 days for those treated in other settings. Significant risk factors associated with readmissions included patients with 3 or more comorbidities, hospitalization 6 months prior to current episode, history of malignancy, and use of vancomycin. Costs of readmissions following POIC-based OPAT resulted in significant savings of 50 percent compared to inpatient readmission costs ($1.36 million versus $2.72 million).

Overall, OPAT management and treatment of septicemia patients at an ID POIC resulted in significantly lower readmission rates, shorter length of second hospitalizations, and significant cost savings. This suggests that provision of optimal therapy under direct supervision of the prescribing physician may impact and lower costly readmissions for septicemia.

This study was presented at IDWeek 2015™. For a printed copy of this research poster study, please call 1.866.654.2451 or email [email protected]. To learn more, click here.


Healix is the national leader in the delivery of parenteral services to medical facilities. The privately-held company is based in Sugar Land, Texas, and offers customizable, turn-key solutions to help healthcare providers offer streamlined infusion therapy and related care.

ABOUT IDWeek 2015™

IDWeek 2015™ is an annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA) and the Pediatric Infectious Diseases Society (PIDS). With the theme “Advancing Science, Improving Care,” IDWeek features the latest science and bench-to-bedside approaches in prevention, diagnosis, treatment, and epidemiology of infectious diseases, including HIV, across the lifespan. IDWeek 2015 took place October 7-11 at the San Diego Convention Center in San Diego, California. For more information, visit www.idweek.org.

Lucinda J. Van Anglen, PharmD
Healix, Inc.
t: 281.295.4000
e: [email protected]

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.